biostudies-literatureSrivastava ANCI NIH HHS169.e1-169.e12https://www.ebi.ac.uk/biostudies/studies/S-EPMC8960351biostudies-literatureUnknown40(4)<h4>Introduction</h4>Testicular germ cell tumors, particularly nonseminomatous germ cell tumors (NSGCT), comprise the most common solid malignancy in male children and younger adults. While these patients experience excellent survival outcomes, few studies have characterized their survival by age. Thus, we aimed to characterize the relative survival of NSGCT by age, stratifying patients by stage group.<h4>Methods</h4>Using the Surveillance Epidemiology and End Results (SEER) database, we divided patients with NSGCT into pediatric patients and adolescents (<19 years), young adults (19-30 years), and older adults (>30 years). Survival analysis, using Cox proportional hazards models and Kaplan Meier curves, described overall and cancer-specific survival (CSS) of each age category for Stage I-Urologic oncologySurvival of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis.PMC8960351P30 CA072720Bagrodia AGupta GNPierorazio PMPatel HVBarone JGElsamra SESrivastava ADrachtman RKoehne EKim IYGhodoussipour SJang TLSinger EAPatel HDfalseSurvival of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis.<h4>Introduction</h4>Testicular germ cell tumors, particularly nonseminomatous germ cell tumors (NSGCT), comprise the most common solid malignancy in male children and younger adults. While these patients experience excellent survival outcomes, few studies have characterized their survival by age. Thus, we aimed to characterize the relative survival of NSGCT by age, stratifying patients by stage group.<h4>Methods</h4>Using the Surveillance Epidemiology and End Results (SEER) database, we divided patients with NSGCT into pediatric patients and adolescents (<19 years), young adults (19-30 years), and older adults (>30 years). Survival analysis, using Cox proportional hazards models and Kaplan Meier curves, described overall and cancer-specific survival (CSS) of each age category for Stage I-2022-01-01T00:00:00Z2022 Apr2025-04-04T18:42:32.391Z2025-04-04T18:42:32.391ZS-EPMC89603513514486510.1016/j.urolonc.2021.12.012